Based on achieving this critical milestone, Aspyrian Therapeutics recently submitted and has received FDA’s acceptance of an Investigational New Drug (IND) Application for RM-1929, their first-in-class, precision targeted
Epic will be responsible for sales and marketing of ELI-200, and Elite will be responsible for the manufacture of the product. Epic will pay Elite non-refundable milestone payments
The Company’s Phase 3 protocol provides for a 25-week study with 300 HIV-positive patients. Selection of clinical sites, IRB approvals, patients screening and other administrative matters are underway
Mission’s wholly-owned subsidiary, ProSolus Inc., offers unrivaled expertise in the development and manufacturing of sophisticated and convenient transdermal (through the skin) drug delivery products to treat a variety
The per share price will be based on the 20-day volume weighted average price (VWAP) of the Company’s Common Stock upon the closing of the acquisition. CBMG will
The second successfully out-licensed biosimilar in the product pipeline is ABY-021, which is a humanized monoclonal antibody for treating immunological symptoms. The out-licensing partner is once again a
Advantar’s manufacturing suite includes an ingress/egress area, weighing and dispensing area and equipment clean up area. The manufacturing area and ingress/egress areas are ISO 8 (Class 100,000), HEPA-filtered
Two of these medicines are for the treatment of psoriasis and a third has been accepted for psoriatic arthritis. The other new medicines accepted are the latest of
The partnership demonstrates Tillotts’ commitment to developing new treatments to improve care for patients with IBD and, upon successful development, will add to a strong track record in
The SEC alleges that Michael J. Fefferman learned material nonpublic information as senior director of information technology at Ardea Biosciences Inc. He tipped his brother-in-law Chad E. Wiegand
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.